PT - JOURNAL ARTICLE AU - Ravichandran, Rajan AU - Purna, Prassana AU - Vijayaragavan, Sivakumar AU - Kalavakollu, Ravi Teja AU - Gaidhane, Shilpa AU - Kumar, Ramarathnam Krishna TI - Efficacy and Safety of Indomethacin in Covid-19 patients AID - 10.1101/2020.12.14.20245266 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.14.20245266 4099 - http://medrxiv.org/content/early/2020/12/16/2020.12.14.20245266.short 4100 - http://medrxiv.org/content/early/2020/12/16/2020.12.14.20245266.full AB - Background Indomethacin, a well-known non-steroidal anti-inflammatory drug (NSAID), has in addition broad spectrum anti-viral activity in the laboratory including on SARS-Cov-2 virus. This trial is to observe the likelihood of efficacy and safety of Indomethacin in treating RT-PCR positive Covid patientsMaterials and Methods The study was done in two groups. In the first group of the study, where mild and moderate patients were involved, Propensity Score Matching was used as a methodology to compare Indomethacin and paracetamol based treatments in addition to the standard protocol for treating covid-19 patients.. Blood chemistry was collected before and after the treatment. The patients were monitored every day for clinical parameters. In this part, a patient developing hypoxia was the end point. In the second group, severe patients admitted with hypoxia were treated with Indomethacin in addition to Remdesivir, and the end point was the requirement of mechanical ventilation/admission to ICU.Results It was observed that patients treated with Indomethacin had a reduction in the number of days to become afebrile, reduction in cough and myalgia by half compared to the paracetamol set. Only one out of 72 patients in the Indomethacin arm of the first group required supplementary oxygen while 28 of the 72 patients required supplementary oxygen in the paracetamol arm. No one in the second group deteriorated enough to require mechanical ventilation. There wea no evidence of adverse reaction to indomethacin or deterioration of renal or liver function.Conclusion Indomethacin, along with standard care, seems to provide faster symptomatic relief and prevent progression of pneumonia in Covid-19 patients. It should be considered to replace paracetamol when there is no contraindication for its use.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN 11970082Funding StatementFunding for this study was provided by Mr. Kris Gopalakrishnan, Alumnus of the Indian Institute of Technology Madras. He is also the Chairman of Axilor Ventures and former executive vice chairman (former co-chairman) of Infosys. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. Approved 03/08/2020, Institutional Ethics Committee, Narayana Medical College (Nellore 524003, India; +91 (0)8008086119; dean{at}narayanamedicalcollege.com), ref: NMC/Ethics/Project/006/2020 2. Approved 10/10/2020, Institutional Ethics Committee, Datta Meghe Institute of Medical Sciences (Sawangi (Meghe), Wardha - 442004, Maharashtra, India; +91 (0)7152 287701; icc.dmims{at}gmail.com), ref: DMIMS(DU)/IEC/2020-21/9034All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe patient data if required can be obtained after ethics committee clearance of the hospital